Analysis reveals that CSF biomarkers for Alzheimer’s disease can enhance diagnostic accuracy, suggesting improved outcomes for patients.
Introduction: In response to demand for accurate and timely diagnosis of Alzheimer’s disease (AD), the Diagnostic Pathology Unit (DPU) at Concord Hospital verified cerebrospinal fluid (CSF) AD biomarkers using the Roche Cobas Pro e801 platform. The CSF AD biomarker panel consists of three assays: β-amyloid (1-42) CSF II, phosphorylated Tau (181P) (pTau) and total Tau (tubulin-associated unit) (tTau).
No takes yet. Share an insight, caveat, or question.
Bono et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: